| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.007 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.007 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.14 | 0.009 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.099 | 0.01 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.01 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.02 |